Dopavision
Andreas is the Chief Technology Officer of Dopavision. He is passionate to merge his experience from product management, software and technology management as well as strategy consulting to make our vision become reality. His healthcare industry experience allows him to ensure Dopavision’s product and processes adhere to the highest regulatory standards. He has previously worked with Meierhofer AG and McKinsey&Company, among others.
This person is not in any offices
Dopavision
1 followers
The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years. Additionally, the company is backed with venture capital in a seed round to advance the research and further develop the product for clinical validation.